Tg Therapeutics Stock Performance
| TGTX Stock | USD 41.89 0.58 1.37% |
On a scale of 0 to 100, TG Therapeutics holds a performance score of 9. The entity owns a Beta (Systematic Risk) of 0.53, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, TG Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding TG Therapeutics is expected to be smaller as well. Please check TG Therapeutics' value at risk, and the relationship between the standard deviation and kurtosis , to make a quick decision on whether TG Therapeutics' current price history will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in TG Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting basic indicators, TG Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.12 | Five Day Return 12.96 | Year To Date Return 36.38 | Ten Year Return 143.31 | All Time Return (81.17) |
Last Split Factor 100:5625 | Last Split Date 2012-04-30 |
1 | Disposition of 11337 shares by Power Sean A of TG Therapeutics at 30.294 subject to Rule 16b-3 | 01/03/2025 |
2 | Acquisition by Power Sean A of 87500 shares of TG Therapeutics subject to Rule 16b-3 | 01/29/2025 |
3 | Acquisition by Weiss Michael S of 750000 shares of TG Therapeutics subject to Rule 16b-3 | 01/30/2025 |
4 | Symphony Financial Ltd. Co. Acquires New Shares in TG Therapeutics, Inc. - MarketBeat | 02/06/2025 |
5 | Acquisition by Weiss Michael S of 100000 shares of TG Therapeutics at 10.13 subject to Rule 16b-3 | 02/21/2025 |
6 | TG Therapeutics Q4 2024 Earnings Preview | 02/28/2025 |
7 | TG Therapeutics Soars Nearly 18 percent as Strong Q4 Results Fuel Growth Optimism | 03/03/2025 |
8 | TG Therapeutics, Inc. Q4 2024 Earnings Call Transcript | 03/04/2025 |
9 | Why TG Therapeutics Stock Was Soaring This Week | 03/07/2025 |
10 | Disposition of 6000 shares by Charney Laurence N of TG Therapeutics subject to Rule 16b-3 | 03/10/2025 |
11 | IBD Live QA And Two Key Stock Lists For March 11, 2025 | 03/11/2025 |
12 | TG Therapeutics Sets New 12-Month High Whats Next | 03/13/2025 |
13 | Disposition of 62459 shares by Hume Daniel of TG Therapeutics subject to Rule 16b-3 | 03/17/2025 |
14 | TG Therapeutics Among the Best Short Squeeze Stocks to Buy According to Analysts | 03/19/2025 |
| Begin Period Cash Flow | 94.2 M |
TGTX |
TG Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,226 in TG Therapeutics on December 21, 2024 and sell it today you would earn a total of 935.50 from holding TG Therapeutics or generate 29.0% return on investment over 90 days. TG Therapeutics is currently generating 0.5005% in daily expected returns and assumes 3.9714% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than TGTX, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TG Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TG Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TG Therapeutics, and traders can use it to determine the average amount a TG Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TGTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.97 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.5 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average TG Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TG Therapeutics by adding it to a well-diversified portfolio.
TG Therapeutics Fundamentals Growth
TGTX Stock prices reflect investors' perceptions of the future prospects and financial health of TG Therapeutics, and TG Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TGTX Stock performance.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0578 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 6.52 B | ||||
| Shares Outstanding | 157.07 M | ||||
| Price To Earning | (4.14) X | ||||
| Price To Book | 30.00 X | ||||
| Price To Sales | 20.00 X | ||||
| Revenue | 329 M | ||||
| Gross Profit | 290.52 M | ||||
| EBITDA | 49.9 M | ||||
| Net Income | 23.38 M | ||||
| Cash And Equivalents | 195.71 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 253.72 M | ||||
| Debt To Equity | 0.62 % | ||||
| Current Ratio | 4.68 X | ||||
| Book Value Per Share | 1.54 X | ||||
| Cash Flow From Operations | (40.52 M) | ||||
| Earnings Per Share | 0.15 X | ||||
| Market Capitalization | 6.58 B | ||||
| Total Asset | 577.69 M | ||||
| Retained Earnings | (1.53 B) | ||||
| Working Capital | 475.68 M | ||||
| Current Asset | 71.33 M | ||||
| Current Liabilities | 16.88 M | ||||
About TG Therapeutics Performance
Evaluating TG Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if TG Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TG Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1 K | 995 | |
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.09 | 0.07 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.11 | 0.11 |
Things to note about TG Therapeutics performance evaluation
Checking the ongoing alerts about TG Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TG Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TG Therapeutics appears to be risky and price may revert if volatility continues | |
| TG Therapeutics currently holds about 195.71 M in cash with (40.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| TG Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: TG Therapeutics Among the Best Short Squeeze Stocks to Buy According to Analysts |
- Analyzing TG Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TG Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining TG Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TG Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TG Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TG Therapeutics' stock. These opinions can provide insight into TG Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.